The Pain Market Outlook to 2016

Introduction

The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods. As such, many different classes of drugs co-exist in the pain market. However, despite the wide range of treatment options, pain remains inadequately managed and substantial market opportunities exist for developers in chronic pain and neuropathic pain.

Features and benefits

* Assess the forecast epidemiology and development of the pain market across the 7MM.
* Analyze the dynamics of the global pain market and understand the impact of key R&D events, market trends, and issues.
* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
* Forecast revenues for major currently marketed and pipeline pain products over 2010–16
* Develop strategies for success in the future global pain market.

Highlights

The global pain market recorded sales of $22.0bn in 2010, rising at a compound annual growth rate (CAGR) of 8.9% from 2005. This growth was supported by the presence of five blockbuster pain drugs - OxyContin, Lyrica, Cymbalta, Celebrex and Lidoderm. However, as patent expiries loom, the global market value is set to contract to $18.7bn by 2016.
The pain pipeline is vast, featuring over 200 drugs in clinical development. Chronic pain remains the most studied indication, although there remains strong interest in neuropathic pain and acute pain. Tapentadol ER has the greatest potential of any pipeline drug, with superior tolerability to OxyContin and potential efficacy in neuropathic pain.
Pfizer was the market-leading company in the global pain market, registering $6.4bn in sales in 2010. Collectively, the top five pain companies accounted for 76.1% of the global market. This dominance is set to wane as their pipelines will be unable to restore market share lost to generics and new product launches.

Your key questions answered

* What are the drivers and resistors of the pain market worldwide?
* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the pain market?
* What is the commercial potential of the most promising compounds in clinical development?
* Who were the leading players in the global pain market in 2010?
[Studien Infos ausblenden]

Executive Summary
Overview and epidemiology of pain
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of pain
Summary
Introduction
Overview
Chronic pain
Chronic low back pain
Osteoarthritis pain
Cancer pain
Fibromyalgia
Acute pain
Post-operative pain
Breakthrough pain
Neuropathic pain
Diabetic neuropathic pain
Post-herpetic neuralgia
Global market analysis
Summary
Introduction
Market analysis by geography
Market analysis by drug class
Narcotic analgesics
NSAIDs
Antiepileptics
Antidepressants
Local anesthetics
Leading brand dynamics
Cymbalta (duloxetine) – Eli Lilly/Shionogi
Lyrica (pregabalin) – Pfizer
Celebrex (celecoxib) – Pfizer
Lidoderm (lidocaine patch) – Teikoku/Endo/Grünenthal
Voltaren (diclofenac) – Novartis
Duragesic (fentanyl patch) – Johnson & Johnson
Loxonin (loxoprofen) – Daiichi Sankyo
Arcoxia (etoricoxib) – Merck
Tegretol (carbamazepine) – Novartis
Key events in the pain market
Pfizer acquires King Pharmaceuticals and its extensive pain portfolio for $3.6bn
FDA enforces clinical hold on tanezumab, later followed by the entire anti-NGF antibody class
First capsaicin patch becomes available for post-herpetic neuralgia
Global pain market sales forecast
Pipeline analysis
Summary
Introduction
Pain pipeline
Leading drugs in development
Profiles of key pipeline products
Tapentadol extended release – Johnson & Johnson/Grünenthal
Stedesa (eslicarbazepine acetate) – Eisai/Dainippon Sumitomo/Bial
Horizant (gabapentin enacarbil) – XenoPort/GlaxoSmithKline/Astellas
Remoxy (oxycodone extended release) – Pfizer/Pain Therapeutics/Durect
Ereska (ketamine spray) – Hospira
Gralise (gabapentin extended release) – Depomed
Oxecta (oxycodone immediate release) – Acura/Pfizer
MoxDuo IR (morphine/oxycodone immediate release) – QRxPharma
Eladur (bupivacaine patch) – Pfizer/Durect
Sativex (nabiximols) – GW Pharmaceuticals/Otsuka/Bayer/Almirall/Novartis
Rylomine (morphine spray) – Hospira/Archimedes
Tanezumab – Pfizer/Rinat Neuroscience
Fentanyl SL – Insys Therapeutics
Exparel (bupivacaine injection) – Pacira Pharmaceuticals
Posidur (bupivacaine injection) – Durect/Nycomed/Hospira
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Sales performance of the leading players
Pfizer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Purdue Pharma
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Eli Lilly
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Novartis
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Johnson & Johnson
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Appendix
Scope
Key pain indications covered in this report
Methodology
Bibliography/References
Glossary/Abbreviations
[Inhaltsverzeichnis ausblenden]